Effects Of Danlou Tablet On The Periprocedural Myocardial Injury Of ACS Patient After Percutaneous Coronary Intervention

BackgroundCoronary heart disease is one of the major disease hazard to human health. The morbidity and mortality of coronary heart disease has been increased with the improvement of people’s living standards and changing of lifestyles. Percutaneous coronary intervention (PCI) has become the preferred treatment of coronary heart disease. However, the major adverse cardiac events, especially periprocedural myocardial injury have not yet been completely resolved by western medicine.ObjectiveObserved effects of Danlou tablet on the periprocedural myocardial injury of ACS patient after PCI. To explore the treatment of Integrative Medicine on acute coronary syndrome after PCI.MethodsIt is a multi-center, randomized, double blind, placebo controlled clinical study, according to the evidence-based medicine requirements and GCP standard. Between Jun.2012 and Dec.2013,88 patients were included in the study and randomly divided into control group (n=42) and treatment group (n=42) from Guangdong Provincial Hospital of TCM and Wuyi Hospital of TCM, who were diagnosed as non ST segment elevation ACS. With the conventional therapy of Western medicine, the control group was given placebo of Danlou tablets while the treatment group was given reallyagent of Danlou tablets. The therapy was begined before PCI and last for three months after PCI. Compare the level of markers of myocardial injury, hs-CRP, lipids of two groups. Then we observe and compare their effects on the periprocedural myocardial injury, periprocedural myocardial infarction and the scores of Seattle angina questionnaire between the two group.ResultsThere were 83 effective cases (94.3%) completed in the study, including 41 cases of the control group (93.2%) and 42 cases of the treatment group (95.5%). Five cases (5.7%) were lost altogether, including 2 cases in the treatment group(4.5%) and 3 cases in the control group(6.8%). The dropout rate between the two groups has no significant difference (P>0.05);Differences in the two groups in gender, height, weight and other cardinal number were not significant (P>0.05), which was comparable. After treatment, periprocedural myocardial injury were occurred 25 cases in each groups.7 cases (16.7%) in the treatment group and 11 cases (26.8%) in the control group occurred periprocedural myocardial infarction (P>0.05). Comparing the MACE events after treatment,8 cases (19%) occurring in the treatment group and 17 cases (41.5%) in the control group. The difference was statistically significant(P<0.05). The SAQ was improvement after treatment both of the two groups, which was significant(P<0.05), but there was no statistically compared with the two groups (P>0.05). ConclusionUnter the conventional therapy of Western medicine, receiving Danlou tablet therapy can protect the myocardial through inhibitting vascular endothelial inflammation, also reduce periprocedural myocardial infarction and major adverse cardiac events for ACS patients. Integrative Medicine has important significance on long-term treatment of acute coronary syndrome after PCI.